Supplementary Table 1.
Demographical, clinical, and TABI correlates for nonprescription opioid use (NPO) during TABI (Chi-square, t-tests)
| Variables | Nonprescription opioid use during TABI |
Unpaired t-test (P)/ Chi-square value (P) | |
|---|---|---|---|
| NO n=25 | YES n=35 | ||
| Demographic | |||
| Age | 26.96 (4.8) | 26.77 (4.38) | 0.16 (0.88) |
| Marital status | |||
| Single | 17 (68%) | 22 (63%) | 0.17 (0.68) |
| Married | 8 (32%) | 13 (37%) | |
| Region | |||
| Urban | 17 (68%) | 26 (74%) | 0.284 (0.59) |
| rural | 8 (32%) | 9 (26%) | |
| Occupation | |||
| Unemployed | 11 (44%) | 15 (43%) | 0.008 (0.93) |
| Employed | 14 (56%) | 20 (57%) | |
| Education | |||
| Less than or equal to high school | 14 (44%) | 20 (43%) | 0.008 (0.93) |
| more than high school | 11 (56%) | 15 (57%) | |
| Socioeconomic status | |||
| Upper middle | 5 (20%) | 9 (26%) | 0.52 (0.77) |
| Lower middle | 13 (52%) | 15 (43%) | |
| Upper lower | 7 (28%) | 11 (31%) | |
| Distance from DDTC (in Km) | 61.88 (88.42) | 67.34 (83.61) | -0.24 (0.80) |
| Clinical | |||
| Form of opioid use | |||
| Heroin | 21 (84%) | 31 (88.5%) | 3.55 (0.31) |
| Heroin and crude opium (Afeem) | 2 (8%) | 3 (8.5%) | |
| Codeine | 0 | 1 (3%) | |
| Adulterated heroin (Smack) | 2 (8%) | 0 | |
| Duration of Opioid use (in years) | 3.8 (2.41) | 4.6 (3.68) | -0.99 (0.35) |
| Comorbid Psychiatric illness | |||
| Major Depressive disorder | 1 (4%) | 0 | 1.42 (0.42) |
| No psychiatric comorbidity | 24 (96%) | 35 (100%) | |
| Comorbid medical illness | |||
| None | 12 (48%) | 18 (51%) | 0.15 (0.92) |
| HCV infection | 11 (44%) | 15 (43%) | |
| HBV infection | 2 (8%) | 2 (6%) | |
| IV route of administration | |||
| Yes | 19 (76%) | 22 (63%) | 1.16 (0.28) |
| No | 6 (24%) | 13 (37%) | |
| Other substance use | |||
| Tobacco | 17 (68%) | 22 (63%) | 1.756 (0.88) |
| Cannabis | 2 (8%) | 3 (8.5%) | |
| Sedatives | 1 (4%) | 2 (5.7%) | |
| None | 2 (8%) | 3 (8.5%) | |
| Tobacco + cannabis | 3 (12%) | 3 (8.5%) | |
| Alcohol + Tobacco + cannabis | 0 | 2 (5.7%) | |
| Reason of starting telemedicine-based home induction | |||
| Difficulty to take leave on consecutive days | 8 (32%) | 13 (37%) | 6.59 (0.16) |
| Distance | 14 (56%) | 16 (45%) | |
| Health issues | 0 | 1 (3%) | |
| Fear of relapse if one goes out of home | 1 (4%) | 0 | |
| Job profile: driving to different city | 2 (8%) | 2 (6%) | |
| Family responsibility | 0 | 3 (9%) | |
| Presence of at least one responsible adult family member | |||
| Yes | 24 (96%) | 32 (91%) | 0.49 (0.63) |
| No | 1 (4%) | 3 (9%) | |
| Relationship of the family member with patient | |||
| Spouse | 8 (32%) | 11 (32%) | 2.50 (0.29) |
| Parent | 15 (60%) | 16 (45%) | |
| Sibling | 2 (8%) | 8 (23%) | |
| Telemedicine mode | |||
| Video mode | 1 (4%) | 2 (6%) | 0.15 (0.93) |
| Audio mode | 16 (64%) | 23 (66%) | |
| Both | 8 (32%) | 10 (28%) | |
| TABI-related: | |||
| Period before starting BNX (in days) | 5 (8.69) | 6.11 (12.40) | -0.39 (0.7) |
| SOWS score on day 1 | 25.76 (11.67) | 25.88 (13.68) | -0.04 (0.97) |
| SOWS score on day 2 (n for no=12; n for yes=26) | 10.33 (6.06) | 7.11 (6.62) | 1.43 (0.16) |
| SOWS score on day 3 (n for no=24) | 6.75 (5.98) | 4.82 (4.95) | 1.34 (0.18) |
| Dose of BPN + NLX (mg) on Day 1 | 5.28 (2.3) | 5.31 (2.32) | -0.57 (0.95) |
| Dose of BPN + NLX (mg) on Day 2 | 5.28 (2.3) | 5.31 (2.32) | -0.57 (0.95) |
| Dose of BPN + NLX (mg) on Day 3 | 5.28 (2.3) | 5.31 (2.32) | -0.57 (0.95) |
| Dose of BPN + NLX (mg) on Day 4 (n for no=3; n for yes=8) | 5 (1) | 5.75 (2.25) | -0.54 (0.6) |
| Dose of BPN + NLX (mg) on Day 5 (n for no=4; n for yes=7) | 4.75 (0.96) | 6.29 (1.79) | -1.56 (0.15) |
| Dose of BPN + NLX (mg) on Day 6 (n for no=4; n for yes=7) | 4.75 (0.96) | 6.29 (1.79) | -1.56 (0.15) |
| delay in follow up by how many days | 0 | 2.8 (3.50) | -3.98 (<0.001)*** |
| Change in dose after 1st day | 2.83 (0.23) | ||
| No change | 24 (96%) | 33 (94%) | |
| Increase | 0 | 2 (6%) | |
| decrease | 1 (4%) | 0 | |
| Follow-up in OPD | 28.58 | ||
| On 7th day | 20 (80%) | 9 (25%) | (<0.001)*** |
| Delayed | 0 | 22 (63%) | |
| No follow-up | 5 (20%) | 2 (6%) | |
| Came early | 0 | 2 (6%) | |
| Dropped out during TABI | 2.88 (0.12) | ||
| Yes | 5 (20%) | 2 (6%) | |
| No | 20 (80%) | 33 (94%) | |
| Reason of Delay (n=22) | |||
| Distance | 0 | 3 | |
| Job issues | 0 | 1 | |
| Family crisis | 0 | 3 | |
| unspecified | 0 | 15 | |
| In-person follow-up on Day 7 | 17.21 | ||
| Yes | 20 (80%) | 9 (26%) | (<0.001)*** |
| No | 5 (20%) | 26 (74%) | |
| Satisfaction with the home induction | |||
| Not satisfied: regrets home induction | 0 | 2 (6%) | 20.7 (0.001)*** |
| Unsure: not sure whether it was right decision | 0 | 11 (31%) | |
| Some satisfaction: wish there was more support from doctor | 2 (8%) | 8 (22%) | |
| Satisfied: it was a right decision; unsure about recommendation | 7 (28%) | 3 (9%) | |
| Very satisfied; will recommend | 11 (44%) | 4 (12%) | |
| Cannot be commented | 5 (20%) | 7 (20%) | |
| Satisfaction with the home induction | 8.28 (0.004)** | ||
| Not satisfied | 5 (25%) | 20 (57.14%) | |
| Satisfied | 20 (75%) | 15 (42.86%) | |
| Any additional calls made by the patient/family between day 4 and 6? | 6.61 (0.12) | ||
| Yes | 3 (12%) | 15 (42%) | |
| No | 22 (88%) | 20 (48%) | |
| Did the patient use nonprescription opioids after TABI (only applicable to those with late follow-up) | 37.5 (<0.001)*** | ||
| Yes | 0 | 28 (80%) | |
| No | 25 (100%) | 7 (20%) | |
| Was the patient on buprenorphine for at least 3 months? | 8.57 | ||
| Yes | 25 (100%) | 25 (71%) | (0.003)** |
| No | 0 | 10 (29%) | |
| During TABI was the dose of BNX increased at any time? | 0.08 (0.78) | ||
| Yes | 5 (20%) | 6 (17%) | |
| No | 20 (80%) | 29 (83%) | |
| Did the patient return extra BNX tables (only for those who did not increase BNX dose during TABI) | 23.46 | ||
| Yes | 20 (80%) | 6 (17%) | (<0.001)*** |
| No | 5 (20%) | 29 (83%) | |
*<0.05; **<0.01; ***<0.001